ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis

详细信息    查看全文

• 作者：Jingwei Jiang (12)
  Xiaohua Liang (12) xiaohualiang2009@gmail.com
  Xinli Zhou (12)
  Ruofan Huang (12)
  Zhaohui Chu (12)
  Qiong Zhan (12)
• 关键词：Carcinoma ; non ; small cell lung – ; Excision repair cross ; complementation group 1 – ; DNA ; binding proteins – ; Drug resistance – ; Neoplasm – ; Meta ; analysis
• 刊名：Molecular Biology Reports
• 出版年：2012
• 出版时间：June 2012
• 年：2012
• 卷：39
• 期：6
• 页码：6933-6942
• 全文大小：547.7 KB
• 参考文献：1. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
  2. Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer. N Engl J Med 350:379–392
  3. van Rens MT, de la Riviere AB, Elbers HR et al (2000) Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117:374–379
  4. Vilmar A, Sorensen JB (2009) Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 64:131–139
  5. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834
  6. Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315:629–634
  7. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101
  8. Bepler G, Olaussen KA, Vataire AL et al (2011) ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol 178:69–78
  9. Wang X, Zhao J, Yang L et al (2010) Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol 27:484–490
  10. Vilmar AC, Santoni-Rugiu E, Sorensen JB (2010) ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 21:1817–1824
  11. Ren S, Zhou S, Zhang L et al (2010) High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Invest 28:1078–1083
  12. Li J, Li ZN, Yu LC et al (2010) Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer 69:116–122
  13. Kang CH, Jang BG, Kim DW et al (2010) The prognostic significance of ERCC1, BRCA1, XRCC1, and beta III-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 68:478–483
  14. Reynolds C, Obasaju C, Schell MJ et al (2009) Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27:5808–5815
  15. Ota S, Ishii G, Goto K et al (2009) Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 64:98–104
  16. Li XQ, Li J, Shi SB et al (2009) Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. Int J Biol Markers 24:230–237
  17. Li J, Li ZN, Du YJ et al (2009) Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. Clin Lung Cancer 10:414–421
  18. Lee HW, Choi YW, Han JH et al (2009) Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer 65:377–382
  19. Ikeda S, Takabe K, Suzuki K (2009) Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathol Int 59:863–867
  20. Holm B, Mellemgaard A, Skov T et al (2009) Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol 27:4254–4259
  21. Azuma K, Sasada T, Kawahara A et al (2009) Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64:326–333
  22. Azuma K, Sasada T, Kawahara A et al (2009) Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol 64:565–573
  23. Okuda K, Sasaki H, Dumontet C et al (2008) Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 62:105–112
  24. Lee KH, Min HS, Han SW et al (2008) ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 60:401–407
  25. Fujii T, Toyooka S, Ichimura K et al (2008) ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 59:377–384
  26. Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800–808
  27. Simon G, Sharma A, Li X et al (2007) Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 25:2741–2746
  28. Cobo M, Isla D, Massuti B et al (2007) Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25:2747–2754
  29. Booton R, Ward T, Ashcroft L et al (2007) ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2:902–906
  30. Azuma K, Komohara Y, Sasada T et al (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98:1336–1343
  31. Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991
  32. Ceppi P, Volante M, Novello S et al (2006) ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17:1818–1825
  33. Bepler G, Kusmartseva I, Sharma S et al (2006) RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24:4731–4737
  34. Simon GR, Sharma S, Cantor A et al (2006) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127:978–983
  35. Lord RV, Brabender J, Gandara D et al (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286–2291
  36. Hirai Y, Yoshimasu T, Oura S et al (2009) Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer. Gan To Kagaku Ryoho 36:611–614
  37. Takenaka T, Yoshino I, Kouso H et al (2007) Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 121:895–900
  38. Ko JC, Su YJ, Lin ST et al (2010) Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells. Biochem Pharmacol 79:655–664
  39. Okuda K, Sasaki H, Hikosaka Y et al (2011) Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer. J Surg Res 168:206–212
  40. De Silva IU, McHugh PJ, Clingen PH et al (2000) Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 20:7980–7990
  41. Nagase S, Tsuboi M, Suzuki K et al (2010) Individualized adjuvant chemotherapy (ACT) based on quantitative excision repair cross-complementing 1 (ERCC1) mRNA expression: a randomized phase II trial in Japanese patients with completely resected non-small cell lung cancer (NSCLC). J Clin Oncol (suppl; abstr e17506)
• 作者单位：1. Department of Oncology, Huashan Hospital, Fudan University, No. 12 Wulumuqi Zhong Road, Shanghai, 200040 China2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200040 China
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Life Sciences
  Animal Anatomy, Morphology and Histology
  Animal Biochemistry
  
• 出版者：Springer Netherlands
• ISSN：1573-4978

文摘

It is hypothesized that high expression of the excision repair cross-complementation group 1 (ERCC1) gene might be a positive prognostic factor, but predict decreased sensitivity to platinum-based chemotherapy. Results from the published data are inconsistent. To derive a more precise estimation of the relationship between ERCC1 and the prognosis and predictive response to chemotherapy of non-small cell lung cancer (NSCLC), a meta-analysis was performed. An electronic search of the PubMed and Embase database was performed. Hazard ratio (HR) for overall survival (OS) was pooled in early stage patients received surgery alone to analyze the prognosis of ERCC1 on NSCLC. HRs for OS in patients received surgery plus adjuvant chemotherapy and in patients received palliative chemotherapy and relative risk (RR) for overall response to chemotherapy were aggregated to analyze the prediction of ERCC1 on NSCLC. The pooled HR indicated that high ERCC1 levels were associated with longer survival in early stage patients received surgery alone (HR, 0.69; 95% confidence interval (CI), 0.58–0.83; P = 0.000). There was no difference in survival between high and low ERCC1 levels in patients received surgery plus adjuvant chemotherapy (HR, 1.41; 95% CI, 0.93–2.12; P = 0.106). However, high ERCC1 levels were associated with shorter survival and lower response to chemotherapy in advanced NSCLC patients received palliative chemotherapy (HR, 1.75; 95% CI, 1.39–2.22; P = 0.000; RR, 0.77; 95% CI, 0.64–0.93; P = 0.007; respectively). The meta-analysis indicated that high ERCC1 expression might be a favourable prognostic and a drug resistance predictive factor for NSCLC.